Analyst Ratings for Watson Pharmaceuticals (WPI)
WPI Rating Summary
WPI Price Target Summary
- Highest: $103.00 (Piper Jaffray)
- Lowest: $70.00 (Jefferies)
- Average: $86.54
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$86.54 (+0.9%)
Avg. $ Target:
$86.54 (+0.9%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/11/2013 | Goldman Sachs | Downgrade | Neutral (Buy) |
96.00 (100.00) |
87.99 | 85.73 | -2.57% | Details |
| 11/2/2012 | Piper Jaffray | Upgrade | Overweight (Neutral) |
103.00 (77.00) |
87.71 | 85.73 | -2.26% | Details |
| 9/18/2012 | Guggenheim | New Coverage | Buy (N/A) |
100.00 (N/A) |
81.39 | 85.73 | 5.33% | Details |
| 7/30/2012 | SunTrust Robinson Humphrey | Downgrade | Neutral (Buy) |
N/A (N/A) |
79.77 | 85.73 | 7.47% | Details |
| 6/22/2012 | Bernstein | Upgrade | Outperform (Market Perform) |
82.00 (80.00) |
69.54 | 85.73 | 23.28% | Details |
| 5/24/2012 | Wells Fargo | Upgrade | Outperform (N/A) |
90.00 (N/A) |
70.71 | 85.73 | 21.24% | Details |
| 4/26/2012 | Citi | Upgrade | Buy (N/A) |
N/A (N/A) |
75.75 | 85.73 | 13.17% | Details |
| 2/15/2012 | Buckingham Research | Upgrade | Buy (N/A) |
75.00 (N/A) |
60.07 | 85.73 | 42.72% | Details |
| 1/25/2012 | BofA/Merrill Lynch | Upgrade | Buy (N/A) |
N/A (N/A) |
55.89 | 85.73 | 53.39% | Details |
| 1/25/2012 | Morgan Stanley | Upgrade | Overweight (N/A) |
N/A (N/A) |
55.89 | 85.73 | 53.39% | Details |
| 1/24/2012 | Cowen | Downgrade | Neutral (N/A) |
N/A (N/A) |
56.00 | 85.73 | 53.09% | Details |
| 12/12/2011 | Credit Agricole | Upgrade | Buy (N/A) |
80.00 (N/A) |
61.52 | 85.73 | 39.35% | Details |
| 12/9/2011 | Barclays » Updated 8/24/2012 |
New Coverage | Overweight (N/A) |
80.00 (N/A) |
61.06 | 85.73 | 40.4% | Details |
| 12/1/2011 | Jefferies | New Coverage | Hold (N/A) |
70.00 (N/A) |
64.62 | 85.73 | 32.67% | Details |
| 9/28/2011 | Canaccord Genuity » Updated 9/24/2012 |
New Coverage | Buy (N/A) |
100.00 (90.00) |
72.10 | 85.73 | 18.9% | Details |
